Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Equity (2019 - 2025)

Allogene Therapeutics' Return on Equity history spans 7 years, with the latest figure at 0.64% for Q3 2025.

  • For Q3 2025, Return on Equity fell 7.0% year-over-year to 0.64%; the TTM value through Sep 2025 reached 0.64%, down 7.0%, while the annual FY2024 figure was 0.55%, 0.0% changed from the prior year.
  • Return on Equity for Q3 2025 was 0.64% at Allogene Therapeutics, up from 0.64% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.19% in Q4 2021 and bottomed at 0.64% in Q2 2025.
  • The 5-year median for Return on Equity is 0.55% (2023), against an average of 0.45%.
  • The largest annual shift saw Return on Equity increased 12bps in 2021 before it plummeted -31bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.19% in 2021, then plummeted by -150bps to 0.47% in 2022, then fell by -22bps to 0.58% in 2023, then rose by 1bps to 0.57% in 2024, then decreased by -11bps to 0.64% in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Return on Equity are 0.64% (Q3 2025), 0.64% (Q2 2025), and 0.62% (Q1 2025).